Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02785406 · ClinicalTrials.gov registry record · Phase 2
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02785406 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants.
The verdict
NCT02785406, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of a medication called suvorexant in reducing anxiety, improving sleep, and reducing cocaine cravings or cocaine use.
Interventions
- DRUG suvorexant
- DRUG Placebo (for suvorexant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-05 |
| Est. Completion | 2018-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02785406
The ClinicalTrials.gov registry entry for NCT02785406 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which suvorexant is the first listed.
NCT02785406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02785406 about?
NCT02785406 is a clinical study titled "Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use". The purpose of this study is to determine the effectiveness of a medication called suvorexant in reducing anxiety, improving sleep, and reducing cocaine cravings or cocaine use.
What is the current status of trial NCT02785406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-05. Estimated completion is 2018-11-15.
What interventions are being tested in trial NCT02785406?
The interventions under investigation include: suvorexant (DRUG), Placebo (for suvorexant) (DRUG).
Who is sponsoring clinical trial NCT02785406?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.